Stephen Harrison Dr. Stephen Harrison, a leading authority on liver diseases, has joined the scientific advisory board (SAB) of Hepion Pharmaceuticals (NASDAQ:HEPA). Dr. Harrison is a visiting professor of hepatology at...
Hepion Pharmaceuticals (NASDAQ:HEPA) has partnered with Applied Pharmaceutical Innovation (API) to expand its research capabilities and further characterize its lead candidate, CRV431. API is an independent institute...
Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...
The FDA has authorized Hepion Pharmaceuticals (NASDAQ:HEPA) to proceed with its IND opening study of CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “Based on the preclinical and clinical studies we’ve...
ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...